Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)
Phase 1
- Conditions
- Non Muscle Invasive Bladder Cancer
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- Patrice Jichlinski
- Target Recruit Count
- 25
- Registration Number
- NCT03421236
- Locations
- 🇨🇭
Dpt Urology- CHUV, Lausanne, Vaud, Switzerland
BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients
Phase 1
Completed
- Conditions
- Bladder Cancer
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2015-02-04
- Lead Sponsor
- Patrice Jichlinski
- Target Recruit Count
- 23
- Registration Number
- NCT01498172
- Locations
- 🇨🇭
Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
News
No news found